{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.72","value":"11.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Pharmacokinetic exposure parameters were estimated for each participant using a population pharmacokinetic (PK) model.","dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib 160 mg twice a day orally with or without food; Obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2 to 6; and then every 8 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; each cycle is 28 days","id":"OG000","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEAN","populationDescription":"The PK Analysis Set included all zanubrutinib-treated participants with ≥1 post-baseline PK concentration (n=142). Concentrations were excluded per prespecified rules (missing/invalid times, pre-dose values, peak-trough switches, and outliers), resulting in 137 participants with reported PK parameters.\n\nconcentration measurement.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1: Predose (within 30 minutes before zanubrutinib dosing) and 2 hours (± 30 minutes) post-dose.","title":"Minimum Observed Concentration (Cmin) of Zanubrutinib at Steady State","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/ml)"}